pubmed-article:21334687 | rdf:type | pubmed:Citation | lld:pubmed |
pubmed-article:21334687 | lifeskim:mentions | umls-concept:C0035647 | lld:lifeskim |
pubmed-article:21334687 | lifeskim:mentions | umls-concept:C0005684 | lld:lifeskim |
pubmed-article:21334687 | lifeskim:mentions | umls-concept:C0194401 | lld:lifeskim |
pubmed-article:21334687 | lifeskim:mentions | umls-concept:C1306673 | lld:lifeskim |
pubmed-article:21334687 | lifeskim:mentions | umls-concept:C1521733 | lld:lifeskim |
pubmed-article:21334687 | lifeskim:mentions | umls-concept:C0220901 | lld:lifeskim |
pubmed-article:21334687 | lifeskim:mentions | umls-concept:C1514983 | lld:lifeskim |
pubmed-article:21334687 | pubmed:issue | 4 | lld:pubmed |
pubmed-article:21334687 | pubmed:dateCreated | 2011-3-22 | lld:pubmed |
pubmed-article:21334687 | pubmed:abstractText | Patients with pathological T3N0 stage urothelial carcinoma of the bladder show a range of outcomes after radical cystectomy. Given that nomograms have included heterogeneous groups of patients, we focused on and stratified patients with pT3N0 urothelial carcinoma of the bladder after radical cystectomy into prognostically different risk groups to facilitate the development of adjuvant therapy trials for those at high risk. | lld:pubmed |
pubmed-article:21334687 | pubmed:language | eng | lld:pubmed |
pubmed-article:21334687 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
pubmed-article:21334687 | pubmed:citationSubset | AIM | lld:pubmed |
pubmed-article:21334687 | pubmed:status | MEDLINE | lld:pubmed |
pubmed-article:21334687 | pubmed:month | Apr | lld:pubmed |
pubmed-article:21334687 | pubmed:issn | 1527-3792 | lld:pubmed |
pubmed-article:21334687 | pubmed:author | pubmed-author:LotanYairY | lld:pubmed |
pubmed-article:21334687 | pubmed:author | pubmed-author:LeeRichardR | lld:pubmed |
pubmed-article:21334687 | pubmed:author | pubmed-author:ShariatShahro... | lld:pubmed |
pubmed-article:21334687 | pubmed:author | pubmed-author:ScherrDouglas... | lld:pubmed |
pubmed-article:21334687 | pubmed:author | pubmed-author:KarakiewiczPi... | lld:pubmed |
pubmed-article:21334687 | pubmed:author | pubmed-author:LernerSeth... | lld:pubmed |
pubmed-article:21334687 | pubmed:author | pubmed-author:DinneyColin... | lld:pubmed |
pubmed-article:21334687 | pubmed:author | pubmed-author:IzawaJonathan... | lld:pubmed |
pubmed-article:21334687 | pubmed:author | pubmed-author:FradetYvesY | lld:pubmed |
pubmed-article:21334687 | pubmed:author | pubmed-author:FicarraVincen... | lld:pubmed |
pubmed-article:21334687 | pubmed:author | pubmed-author:KassoufWassim... | lld:pubmed |
pubmed-article:21334687 | pubmed:author | pubmed-author:AmielGilad... | lld:pubmed |
pubmed-article:21334687 | pubmed:author | pubmed-author:NovaraGiacomo... | lld:pubmed |
pubmed-article:21334687 | pubmed:author | pubmed-author:KhanMyrna MMM | lld:pubmed |
pubmed-article:21334687 | pubmed:author | pubmed-author:SonpavdeGuruG | lld:pubmed |
pubmed-article:21334687 | pubmed:author | pubmed-author:BastianPatric... | lld:pubmed |
pubmed-article:21334687 | pubmed:author | pubmed-author:SkinnerEilaE | lld:pubmed |
pubmed-article:21334687 | pubmed:author | pubmed-author:TilkiDeryaD | lld:pubmed |
pubmed-article:21334687 | pubmed:author | pubmed-author:SvatekRobert... | lld:pubmed |
pubmed-article:21334687 | pubmed:author | pubmed-author:FritscheHans-... | lld:pubmed |
pubmed-article:21334687 | pubmed:copyrightInfo | Copyright © 2011 American Urological Association Education and Research, Inc. Published by Elsevier Inc. All rights reserved. | lld:pubmed |
pubmed-article:21334687 | pubmed:issnType | Electronic | lld:pubmed |
pubmed-article:21334687 | pubmed:volume | 185 | lld:pubmed |
pubmed-article:21334687 | pubmed:owner | NLM | lld:pubmed |
pubmed-article:21334687 | pubmed:authorsComplete | Y | lld:pubmed |
pubmed-article:21334687 | pubmed:pagination | 1216-21 | lld:pubmed |
pubmed-article:21334687 | pubmed:meshHeading | pubmed-meshheading:21334687... | lld:pubmed |
pubmed-article:21334687 | pubmed:meshHeading | pubmed-meshheading:21334687... | lld:pubmed |
pubmed-article:21334687 | pubmed:meshHeading | pubmed-meshheading:21334687... | lld:pubmed |
pubmed-article:21334687 | pubmed:meshHeading | pubmed-meshheading:21334687... | lld:pubmed |
pubmed-article:21334687 | pubmed:meshHeading | pubmed-meshheading:21334687... | lld:pubmed |
pubmed-article:21334687 | pubmed:meshHeading | pubmed-meshheading:21334687... | lld:pubmed |
pubmed-article:21334687 | pubmed:meshHeading | pubmed-meshheading:21334687... | lld:pubmed |
pubmed-article:21334687 | pubmed:meshHeading | pubmed-meshheading:21334687... | lld:pubmed |
pubmed-article:21334687 | pubmed:meshHeading | pubmed-meshheading:21334687... | lld:pubmed |
pubmed-article:21334687 | pubmed:meshHeading | pubmed-meshheading:21334687... | lld:pubmed |
pubmed-article:21334687 | pubmed:meshHeading | pubmed-meshheading:21334687... | lld:pubmed |
pubmed-article:21334687 | pubmed:year | 2011 | lld:pubmed |
pubmed-article:21334687 | pubmed:articleTitle | Prognostic risk stratification of pathological stage T3N0 bladder cancer after radical cystectomy. | lld:pubmed |
pubmed-article:21334687 | pubmed:affiliation | Michael E. DeBakey Veterans Affairs Medical Center, Dallas, Texas, USA. gurus@bcm.edu | lld:pubmed |
pubmed-article:21334687 | pubmed:publicationType | Journal Article | lld:pubmed |
pubmed-article:21334687 | pubmed:publicationType | Research Support, U.S. Gov't, Non-P.H.S. | lld:pubmed |